ADVM · As filed with the SEC

Adverum Biotechnologies balance sheet, by quarter

The statement as Adverum Biotechnologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Condensed Consolidated Balance Sheets · USD thousands, except per-share amounts; shares in thousands

USD thousands, except per-share amounts; shares in thousands	Q3 2025 Sep 30, 2025	Q2 2025 Jun 30, 2025	Q1 2025 Mar 31, 2025	Q4 2024 Dec 31, 2024	Q3 2024 Sep 30, 2024	Q4 2023 Dec 31, 2023
Assets
Current assets:
Cash and cash equivalents	26,060	42,418	49,161	60,652	92,851	75,000
Short-term investments	0	1,979	33,922	65,039	60,390	21,526
Prepaid expenses and other current assets	2,849	3,994	6,386	5,609	7,839	6,247
Total current assets	28,909	48,391	89,469	131,300	161,080	102,773
Operating lease right-of-use assets	29,031	33,529	33,584	33,611	50,695	52,266
Property and equipment, net	10,462	10,811	11,135	11,607	12,215	14,764
Deferred rent receivable	—	—	—	—	7,116	—
Restricted cash	1,976	1,976	1,976	1,976	1,976	1,976
Deposit and other long-term assets	2,023	1,472	1,490	1,347	1,293	1,231
Total assets	72,401	96,179	137,654	179,841	234,375	173,010
Liabilities and stockholders’ (deficit) equity
Current liabilities:
Accounts payable	12,459	4,748	1,819	1,610	2,110	1,921
Accrued expenses and other current liabilities	26,476	19,245	16,046	15,620	14,886	12,584
Lease liability, current portion	5,814	7,363	7,229	5,668	10,661	10,409
Total current liabilities	44,749	31,356	25,094	22,898	27,657	24,914
Lease liability, net of current portion	83,126	84,858	85,949	86,037	62,602	64,627
Other non-current liabilities	179	184	189	192	—	0
Total liabilities	128,054	116,398	111,232	109,127	90,259	89,541
Stockholders’ (deficit) equity:
Preferred stock	0	0	0	0	0	0
Common stock	2	2	2	2	2	10
Additional paid-in capital	1,155,598	1,143,391	1,140,848	1,138,070	1,134,556	1,003,709
Accumulated other comprehensive loss	(440)	(451)	(458)	(407)	(268)	(473)
Accumulated deficit	(1,210,813)	(1,163,161)	(1,113,970)	(1,066,951)	(990,174)	(919,777)
Total stockholders’ (deficit) equity	(55,653)	(20,219)	26,422	70,714	144,116	83,469
Total liabilities and stockholders’ (deficit) equity	72,401	96,179	137,654	179,841	234,375	173,010
Common stock, shares issued (in shares)	—	—	—	20,848	—	—
Common stock, shares outstanding (in shares)	—	—	—	20,848	—	—
Common stock, shares authorized (in shares)	—	—	—	300,000	—	—
Common stock, par value (in USD per share)	—	—	—	0.00	—	—

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.